- Home
- DFP vs ALT Comparison
DFP vs ALT Comparison
Compare DFP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFP | ALT |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.4M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DFP | ALT |
|---|---|---|
| Price | $20.86 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 67.9K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $19.09 | $2.87 |
| 52 Week High | $22.11 | $7.73 |
Technical Indicators
Market Signals| Indicator | DFP | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 42.47 |
| Support Level | $20.39 | $2.87 |
| Resistance Level | $20.98 | $4.25 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 96.28 | 60.45 |
Price Performance
Historical ComparisonAbout DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.